Therapeutic Efficacy of Fuzheng-Huayu Tablet Based Traditional Chinese Medicine Syndrome Differentiation on Hepatitis-B-Caused Cirrhosis : A Multicenter Double-Blind Randomized Controlled Trail

Abstract EN

Aim.

To evaluate and predict the therapeutic efficacy of Fuzheng-Huayu tablet (FZHY) based traditional Chinese Medicine (TCM) syndrome differentiation or TCM symptoms on chronic hepatitis B caused cirrhosis (HBC).

Methods.

The trial was designed according to CONSORT statement.

It was a multi-center, double-blind, randomized, placebo-controlled trail.

Several clinical parameters, Child-Pugh classification and TCM symptoms were detected and evaluated.

The FZHY efficacy was predicted by an established Bayes forecasting method following the Bayes classification model.

Results.

The levels of HA and TCM syndrome score in FZHY group were significantly decreased (P<0.05) compared to placebo group, respectively.

The efficacy of FZHY on TCM syndrome score in HBC patients with some TCM syndromes was better.

In TCM syndrome score evaluation, there were 53 effective and 22 invalid in FZHY group.

TCM symptoms predicted FZHY efficacy on HBC were close to Child-Pugh score prediction.

Conclusion.

FZHY decreases the levels of HA and TCM syndrome scores, improves the life quality of HBC patients.

Moreover, there were different therapeutic efficacies among different TCM syndromes, indicating that accurate TCM syndrome differentiation might guide the better TCM treatment.

Furthermore, the FZHY efficacy was able to predict by Bayes forecasting method through the alteration of TCM symptoms.